No Marshmallows, Just Term Papers
Phyto-Riker, a U.S. investor-led start-up pharmaceutical company in Ghana, contemplates the effects of needs generated by the HIV epidemic in sub-Saharan Africa on its future business plans.
In April 2001, it appeared as if political will was crystallizing around the world that substantial resources needed to be devoted to fighting the epidemic. It was not certain what amount of resources would be available, or how the resources would be expended. But in the meantime, public health officials, AIDS activists, philanthropists, and pharmaceutical companies were engaged in various activities designed to address the HIV problem from their own points of view.
AIDS crisis in Africa
The Sub-Saharan Africa was more heavily affected by HIV and AIDS than any other of the regions of the world. Two out of three people that have contracted AIDS are living in this area of the world that has been totaled out to be around 22.9 million people. From studies conducted in 2010, it became known that 1.2 million people had died from AIDS while around 1.9 million people were infected with HIV. Children were greatly affected, 14.8 million children in the region had lost one or both parents to the disease and it seems many will sometime in the future contract AIDS or HIV if they haven’t already.
We had found three major problems that wasn’t helping Phyto-Riker Pharmaceuticals to get into the market of creating drugs for AIDs which included:
One major problem Phyto-Riker faced in entering the market was extreme competition from pharmaceutical companies developing antiretroviral drugs. They also had the problem of generic drugs against non-generic drugs and trying to secure a patent for their drug. Their other major problem would be trying to get funding for R&D, drugs, and equipment and relying on getting enough donations to support themselves in the market.
One of the things Phyto-Riker could do to fight...